March 4, 2017
Eli Lilly and Company has announced that patients with moderate-to-severe plaque psoriasis treated with Taltz® (ixekizumab) demonstrated superior efficacy at 24 weeks compared to patients treated with Stelara®* (ustekinumab). Detailed results from the IXORA-S study were presented during the American Academy of Dermatology (AAD) Annual Meeting taking place March 3-7 in Orlando, Fla.
Kristian Reich, M.D., Ph.D., lead author and professor, Georg-August-University Göttingen and Dermatologikum Hamburg, Hamburg, Germany, said: “For many years, achieving PASI 75 – or 75 percent improvement in skin plaques – has been the standard treatment goal for moderate-to-severe plaque psoriasis. With the introduction of treatments like Taltz, dermatologists can offer treatment options that allow more patients to achieve PASI 90 or PASI 100. The data of the IXORA-S study is significant, as it demonstrates both high levels of skin improvement for patients treated with Taltz, consistent with pivotal Phase 3 trials, as well as higher response rates over Stelara, which is one of the most frequently used biologics in the treatment of moderate-to-severe plaque psoriasis.”
“The approval of Taltz in the U.S., Canada and Europe nearly one year ago introduced a treatment option that could help patients with moderate-to-severe plaque psoriasis achieve virtually clear or completely clear skin. We are thrilled with the opportunity to share this new data with dermatologists at AAD, as it reinforces the clinical benefits of Taltz for patients with moderate-to-severe plaque psoriasis,” said Dr. Lotus Mallbris, global brand development leader, Taltz, Eli Lilly and Company.